NHF adds lupus to Individual Benefits Programme
As of April 30, 2019, NHF will offer 18 Active Pharmaceutical Ingredients (APIs) for the treatment of Systemic Lupus Erythematosus (Lupus), under the fund’s Individual Benefits programme.
This is expected to reduce the impact of this life-threatening disease and improve patients' quality of life, through improved access to medication.
Currently, 6,000 individuals in Jamaica are living with Lupus.
“I am extremely happy that the NHF is able to respond to the health care needs of Jamaicans. Under this new arrangement, persons living with Lupus will benefit through the NHF Card Programme,” said Everton Anderson, CEO, NHF.
Patients with Lupus wishing to access this benefit must apply for the NHF Card by completing the yellow application form. A TRN is required. If the patient has already been enrolled for another condition covered by NHF, a Change Form must be completed. Both forms must be signed by a doctor.
Lupus is a disease in which the body's immune system attacks the organs of the body. Patients with this condition are at risk for a number of complications including arthritis, neurological problems such as strokes and seizures, as well as renal complications.